Heart Failure Spotlight: Jardiance® (empagliflozin) tablets: The Impact of EMPA-REG OUTCOME

This program reviews efficacy and safety data from the EMPA-REG OUTCOME trial. It provides information on JARDIANCE initiation and dosing, as well as guidance for monitoring patients on JARDIANCE.
Speaker:
Narendra Singh, MD, FRCPC, FCCS, FACC, FAHA
Clinical Assistant Professor, Medical College of Georgia at Augusta University
Director of Clinical Research, NSC Cardiology
Johns Creek, Georgia
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
#heartfailure #ACC21